Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors

Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard‐of‐care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF‐prolyl hydroxylase inhibitors (HIF‐PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia‐Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF‐PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia‐Pacific region who have clinical experience or have been investigators in HIF‐PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF‐PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF‐PHI, taking into account both available data and expert opinion in areas where evidence remains scarce.

[1]  Sohita Dhillon Daprodustat: First Approval , 2020, Drugs.

[2]  A. Markham Vadadustat: First Approval , 2020, Drugs.

[3]  P. Zhu,et al.  Oxygen homeostasis and cardiovascular disease: A role for HIF? , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  M. Iwasaki,et al.  Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. , 2020, Journal of the American Society of Nephrology : JASN.

[5]  Tetsuhiro Tanaka,et al.  Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. , 2020, Current opinion in nephrology and hypertension.

[6]  J. Laliberté,et al.  Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor , 2020, Toxicologic pathology.

[7]  Stefanie Kapsa,et al.  Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF–PH inhibitor for the treatment of renal anaemia , 2020, European Journal of Clinical Pharmacology.

[8]  T. Akizawa,et al.  Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  Ajay K. Singh,et al.  Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. , 2019, Current opinion in nephrology and hypertension.

[10]  A. Cobitz,et al.  A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis , 2019, BMC Nephrology.

[11]  Tetsuhiro Tanaka,et al.  JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. , 2019, European journal of pharmacology.

[12]  J. Nathans,et al.  Roles of HIFs and VEGF in angiogenesis in the retina and brain. , 2019, The Journal of clinical investigation.

[13]  N. Gupta,et al.  The stimulation of thrombosis by hypoxia. , 2019, Thrombosis research.

[14]  T. Akizawa,et al.  Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[15]  L. Szczech,et al.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. , 2019, The New England journal of medicine.

[16]  L. Szczech,et al.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. , 2019, The New England journal of medicine.

[17]  M. Nangaku,et al.  Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial , 2019, Nephron.

[18]  F. Shaikh,et al.  Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study , 2019, American Journal of Nephrology.

[19]  M. Iwasaki,et al.  Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial , 2019, Advances in Therapy.

[20]  I. Macdougall,et al.  Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies , 2019, American Journal of Nephrology.

[21]  M. Nangaku,et al.  A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial , 2019, American Journal of Nephrology.

[22]  A. Pezzuto,et al.  Role of HIF-1 in Cancer Progression: Novel Insights. A Review. , 2019, Current molecular medicine.

[23]  I. Macdougall,et al.  Effects of Molidustat in the Treatment of Anemia in CKD. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[24]  G. Schley,et al.  HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. , 2018, Kidney international.

[25]  Tianbiao Zhou,et al.  The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease , 2018, Drug design, development and therapy.

[26]  Tetsuhiro Tanaka,et al.  Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease , 2018, Current opinion in nephrology and hypertension.

[27]  G. Chertow,et al.  Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  J. Lepore,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis , 2018, Clinical kidney journal.

[29]  Sung Gyun Kim,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease , 2018, Clinical kidney journal.

[30]  D. Tenero,et al.  The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects , 2018, Pharmacology research & perspectives.

[31]  I. Macdougall,et al.  New options for the anemia of chronic kidney disease , 2017, Kidney international supplements.

[32]  U. Del Balzo,et al.  Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats , 2017, International journal of toxicology.

[33]  Qingbo Xu,et al.  Hypoxia inducible factor as a therapeutic target for atherosclerosis. , 2017, Pharmacology & therapeutics.

[34]  Tetsuhiro Tanaka,et al.  Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. , 2017, Kidney international.

[35]  Tetsuhiro Tanaka,et al.  Epigenetic Changes in the Acute Kidney Injury-to-Chronic Kidney Disease Transition , 2017, Nephron.

[36]  S. Hemmerich,et al.  Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  B. Maroni,et al.  Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease , 2017, American Journal of Nephrology.

[38]  E. Grande,et al.  Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. , 2017, Critical reviews in oncology/hematology.

[39]  I. Macdougall,et al.  Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients , 2017, American Journal of Nephrology.

[40]  Michael R. Padgen,et al.  Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments , 2017, Nature Cell Biology.

[41]  M. Nangaku,et al.  Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects , 2016, American Journal of Nephrology.

[42]  V. Haase,et al.  Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. , 2016, Kidney international.

[43]  D. Cornfield,et al.  Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. , 2016, Kidney international.

[44]  James E. Novak,et al.  Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[45]  M. Sahay,et al.  A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  S. Hemmerich,et al.  Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  I. Macdougall,et al.  SP309SAFETY AND EFFICACY OF MOLIDUSTAT IN ERYTHROPOIESIS STIMULATING AGENTS (ESA) PRE-TREATED ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND) , 2016 .

[48]  I. Macdougall,et al.  SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND) , 2016 .

[49]  A. Rastogi,et al.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. , 2016, Journal of the American Society of Nephrology : JASN.

[50]  S. Hemmerich,et al.  Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. , 2016, Journal of the American Society of Nephrology : JASN.

[51]  T. Fields,et al.  The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice , 2016, Molecular and Cellular Biology.

[52]  Mahboob Rahman,et al.  Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[53]  Y. Baba,et al.  Signals controlling the development and activity of regulatory B-lineage cells. , 2015, International immunology.

[54]  S. Hemmerich,et al.  Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  F. Kronenberg,et al.  Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study , 2015, PloS one.

[56]  Y. Asada,et al.  Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity , 2015, Thrombosis and Haemostasis.

[57]  Tetsuhiro Tanaka,et al.  Hypoxia as a key player in the AKI-to-CKD transition. , 2014, American journal of physiology. Renal physiology.

[58]  J. McKeating,et al.  Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. , 2014, Journal of hepatology.

[59]  J. Phillips,et al.  Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease. , 2014, American journal of physiology. Regulatory, integrative and comparative physiology.

[60]  Tetsuhiro Tanaka,et al.  Role of hypoxia in progressive chronic kidney disease and implications for therapy , 2014, Current opinion in nephrology and hypertension.

[61]  G. Schley,et al.  Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion. , 2014, Journal of the American Society of Nephrology : JASN.

[62]  V. Haase,et al.  Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. , 2012, The Journal of clinical investigation.

[63]  C. Peyssonnaux,et al.  Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis , 2012, Haematologica.

[64]  P. Thistlethwaite,et al.  Unfavourable consequences of chronic cardiac HIF-1α stabilization. , 2012, Cardiovascular research.

[65]  F. Gonzalez,et al.  Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. , 2011, Gastroenterology.

[66]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[67]  D. Gale,et al.  Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. , 2011, Blood.

[68]  A. Frost,et al.  A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance , 2010, International journal of general medicine.

[69]  M. Nangaku,et al.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease , 2010, Nature Reviews Nephrology.

[70]  D. Neuberg,et al.  Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy , 2010, Circulation.

[71]  R. Shohet,et al.  Conditional HIF-1α Expression Produces a Reversible Cardiomyopathy , 2010, PloS one.

[72]  G. Semenza HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[73]  Tetsuhiro Tanaka,et al.  The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease , 2010, Current opinion in nephrology and hypertension.

[74]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[75]  C. Peyssonnaux,et al.  HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. , 2009, The Journal of clinical investigation.

[76]  F. Gonzalez,et al.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. , 2009, Cell metabolism.

[77]  C. Bartram,et al.  Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF 2 , 2008 .

[78]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[79]  W. Weichert,et al.  Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. , 2007, The American journal of pathology.

[80]  H. Krum,et al.  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis , 2007, The Lancet.

[81]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[82]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[83]  P. Thistlethwaite,et al.  Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. , 2005, Journal of the American College of Cardiology.

[84]  M. Nangaku Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[85]  P. Carmeliet,et al.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. , 2003, The Journal of clinical investigation.

[86]  David Mole,et al.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.

[87]  Kai-Uwe Eckardt,et al.  Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. , 2002, Journal of the American Society of Nephrology : JASN.

[88]  L. Bianchi,et al.  Transferrin Receptor Induction by Hypoxia , 1999, The Journal of Biological Chemistry.

[89]  M. Gassmann,et al.  Oxygen-regulated Transferrin Expression Is Mediated by Hypoxia-inducible Factor-1* , 1997, The Journal of Biological Chemistry.

[90]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[91]  H. Scholz,et al.  Erythropoietin in polycystic kidneys. , 1989, The Journal of clinical investigation.

[92]  A. Besarab,et al.  Dynamics of erythropoiesis following renal transplantation. , 1987, Kidney international.

[93]  Tetsuhiro Tanaka,et al.  Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. , 2019, Contributions to nephrology.

[94]  I. Koulouridis,et al.  Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[95]  K. Eckardt,et al.  Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. , 2008, The Biochemical journal.